✦ LIBER ✦

Minimizing Repolarization-Related Proarrhythmic Risk in Drug Development and Clinical Practice

✍ Scribed by Attila S. Farkas, Dr Stanley Nattell

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Understanding proarrhythmic potential in

✍ Robert L. Lux; Leonard S. Gettes; Jay W. Mason 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 257 KB

Reducing QT liability and proarrhythmic

✍ Jean-Pierre Valentin 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 424 KB

Pharmacogenomics in clinical practice an

✍ Harper, Andrew R; Topol, Eric J 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 498 KB

Drug development risk in HIV-1 clinical

✍ Brendan J.W. Osborne; Rupert Kaul; Jayson L. Parker 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 519 KB

Symposium on Quality Assurance and Good

✍ A. L. Kranich; G. Gastl; H. Maier-Lenz; G. A. Nagel 📂 Article 📅 1994 🏛 Springer-Verlag 🌐 English ⚖ 375 KB

Benefit and Risk Assessment in Drug Deve

✍ Honig, P 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 75 KB